(Q45778975)

English

The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys

scientific article published on 27 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys (English)

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

0 references

author name string

D Roy

1

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

K D Chadwick

2

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

K Tatarkiewicz

3

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

C LaCerte

4

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

A-M Bergholm

5

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

T Brodie

6

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

R S Mangipudy

7

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

D Parkes

8

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

M J Graziano

9

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

T P Reilly

10

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

publication date

27 April 2014

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

16

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

10

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

910-921

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Exenatide-induced acute pancreatitis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Exenatide (exendin-4)-induced pancreatitis: a case report.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

A cohort study of acute pancreatitis in relation to exenatide use.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Incretin therapy and islet pathology: a time for caution

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Regulatory forum opinion piece: blind reading of histopathology slides in general toxicology studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Use of Ranks in One-Criterion Variance Analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Exenatide-induced chronic damage of pancreatic tissue in rats

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

GLP-1-based therapy for diabetes: what you do not know can hurt you.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Do GLP-1-based therapies increase cancer risk?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12294

21 January 2018

Identifiers

10.1111/DOM.12294

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24666399

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45778975&oldid=2082298505"